Perrigo Company (PRGO 57.48, +0.04, +0.07%) announced that it has it received FDA clearance on August 23, 2010 to manufacture infant formula liquid concentrate and ready-to-use products through its partner Kerry Proteins and Nutritionals located in Sainte Claire, Quebec. Perrigo received clearance to market the following new products:
Milk-Based Infant Formula with ARA and DHA, Concentrate in a 13 oz multilayer high-barrier polypropylene bottle
Milk-Based Infant Formula with ARA and DHA, Ready-to-Use Infant Formula in an 8 oz multilayer high-barrier polypropylene bottle
Milk-Based Organic Infant Formula with ARA/DHA, Liquid Ready-to-Feed Infant Formula in an 8 oz multilayer high-barrier polypropylene bottle
Perrigo's Chairman and CEO Joseph C. Papa stated, "We are excited to receive FDA clearance on these new liquid concentrate and ready-to-use products and to expand our portfolio of non-powder infant formula products. This is the first launch of new products since acquiring our infant nutrition business and we look forward to further new product introductions."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).